Biotechnology Innovation Organization

The FDA’s PRV program, now expired, is vital for developing treatments for rare pediatric diseases and supporting U.S. innovation leadership. Now, patient advocates and #biotech leaders across the U.S. are urging immediate reauthorization: bio.news/health/bio-202…

Against the broad spectrum of technology sectors, biomanufacturers face many hurdles in protecting and attaining patents critical for broadening treatment application and patient accessibility. BIO's Dr. Hans Sauer explains: bio.news/federal-policy…

Biotech leaders: Strong intellectual property (IP) protections are essential to sustaining U.S. innovation leadership and ensuring expanded patient access to lifesaving treatments. Read more: bio.news/bio-convention…

.@Alnylam CEO @ygreenst underscores the urgency for congressional action on the #MINIAct to support small #biotech companies advancing #GeneticallyTargetedTechnologies. Fixing the #IRA’s treatment of GTT is key to protecting future breakthroughs: bit.ly/4lQcbNM

The Rare Pediatric Disease PRV program has expired and without immediate reauthorization, the pipeline for lifesaving pediatric rare disease treatments will stall. Patients can’t wait. Learn more: bio.news/health/bio-202…

Last week, BIO President & CEO John F. Crowley visited Virginia as part of #BIOontheAmericanRoad, highlighting the state’s booming #biotech ecosystem. Since 2022, Virginia has invested $1B+ in R&D, creating 400+ new patents and driving innovation forward. bio.news/latest-news/bi…

“BIO is at the epicenter of coming up with groundbreaking policy solutions that actually can change the healthcare paradigm in the U.S.” BIO sat down with our new board chair, Fritz Bittenbender. bio.news/bio-convention…

Fully vaccinating individuals saves an estimated $4,637 in medical costs per person. Learn more about the critical role immunization plays in protecting our communities and economy: whywevaccinate.org #WhyWeVaccinate

#BIOontheAmericanRoad is in Virginia! BIO President and CEO John F. Crowley, alongside @vabio, toured @PhlowUSA's state-of-the-art pharmaceutical manufacturing facility in Petersburg, focused on improving the resiliency of American pharmaceutical supply chains + development.

BIO on the American Road is back – and we’re heading to Richmond, VA this week! Stay tuned for updates as we celebrate and hear from local #biotech leaders alongside @vabio.

Today, members of BIO's Women's Health Task Force took to Capitol Hill, highlighting the vital role of female #biotech leaders in driving U.S. innovation and advocating for robust investments in women's health research.

Onerous reporting rules are crushing small biotechs, BIO Board member testifies. Full story on Bio.News: bio.news/federal-policy…

Strong U.S. biodefense depends on public-private partnerships, experts say. Read more on Bio.News: bio.news/bio-convention…

Routine childhood immunizations have protected more than 117 million children in the U.S.—preventing disease, hospitalizations, and over 1 million deaths. Learn more: whywevaccinate.org

#ICYMI BIO caught up with @MassGovernor Maura Healey at #BIO2025, who shared how Massachusetts is investing in #biotech innovation to drive critical health and economic advancements for families across the state.

The #biotech industry drives America's competitiveness and strengthens our communities. ✅Supports over 2 million jobs directly & an additional 8 million jobs indirectly ✅Generates over $3 trillion in total economic output Learn more: bio.org/value-bioscien…